NCT04101968 The GBA Multimodal Study in Parkinson's Disease
| NCT ID | NCT04101968 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pacific Parkinson's Research Centre |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2019-05-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2019-05-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Eligibility Criteria
Inclusion Criteria: * heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism; * age 18 to 80 years. Exclusion Criteria: * co-occurrence of other neurological disorders; * implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices); * severe claustrophobia; * intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects); * ongoing treatment with cholinergic drugs
Contact & Investigator
Michele Matarazzo, MD
PRINCIPAL INVESTIGATOR
Pacific Parkinson's Research Centre | University of British Columbia
Frequently Asked Questions
Who can join the NCT04101968 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04101968 currently recruiting?
Yes, NCT04101968 is actively recruiting participants. Contact the research team at jess.mckenzie@ubc.ca for enrollment information.
Where is the NCT04101968 trial being conducted?
This trial is being conducted at Portland, United States, Seattle, United States, Vancouver, Canada.
Who is sponsoring the NCT04101968 clinical trial?
NCT04101968 is sponsored by Pacific Parkinson's Research Centre. The principal investigator is Michele Matarazzo, MD at Pacific Parkinson's Research Centre | University of British Columbia. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.